Stock traders buy high volume uniQure call options (NASDAQ:QURE)

uniQure Inc (NASDAQ:QURE) saw unusually heavy options trading activity on Friday. Traders bought 5,496 call options on the stock. This represents an increase of approximately 929% over the average volume of 534 call options.

QURE has been the subject of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on uniQure stock in a Tuesday, October 26 research report. Raymond James downgraded uniQure shares from a ‘strong buy’ rating to an ‘outperform’ rating and cut his price target for the company from $75.00 to $58.00 in a Thursday research report December 16. upgraded uniQure’s shares from a “sell” rating to a “hold” rating in a Saturday, Feb. 5 research report. William Blair launched coverage on uniQure shares in a research report on Wednesday, October 27. They issued an “outperform” rating and a price target of $66.00 on the stock. Finally, Zacks Investment Research downgraded uniQure’s shares from a “buy” rating to a “hold” rating in a research report on Thursday. Three investment analysts gave the stock a hold rating and nine gave the stock a buy rating. According to MarketBeat, the stock currently has an average buy rating and an average price target of $55.38.

Separately, Vice Chairman Alexander Edward Kuta III sold 6,000 shares of the company in a transaction dated Wednesday, December 15. The shares were sold at an average price of $27.90, for a total transaction of $167,400.00. The transaction was disclosed in a document filed with the SEC, accessible via this hyperlink. Additionally, CFO Christian Klemt sold 3,963 shares of the company in a trade dated Wednesday, January 26. The stock was sold at an average price of $18.03, for a total transaction of $71,452.89. The disclosure of this sale can be found here. In the past 90 days, insiders have sold 32,157 shares of the company worth $722,636. Insiders hold 2.66% of the shares of the company.

(A d)

Don’t be fooled by other guides showing their unique or horribly outdated business examples.

“Options Basics” will give you real, real-time trade examples to help you grow your account while minimizing risk!

Major investors have recently changed their stake in the company. Dark Forest Capital Management LP acquired a new stake in uniQure in the second quarter worth approximately $27,000. First Quadrant LP CA acquired a new position in uniQure during the fourth quarter worth $37,000. First Horizon Advisors Inc. increased its holdings in uniQure by 489.2% during the third quarter. First Horizon Advisors Inc. now owns 383 shares of the biotech company worth $38,000 after buying 318 more shares in the last quarter. Rockefeller Capital Management LP acquired a new position in uniQure during the third quarter worth $41,000. Finally, Future Financial Wealth Management LLC acquired a new position in uniQure during the fourth quarter worth $43,000. 78.95% of the shares are held by hedge funds and other institutional investors.

Shares of QURE traded down $0.21 on Friday, hitting $16.83. 538,429 shares of the company were traded, against an average volume of 499,484. uniQure has a 12-month low of $15.89 and a 12-month high of $38.80. The company has a current ratio of 14.16, a quick ratio of 14.17 and a debt ratio of 0.12. The stock has a market capitalization of $777.78 million, a P/E ratio of 2.49 and a beta of 1.01. The company has a 50-day moving average price of $20.97 and a two-hundred-day moving average price of $27.39.

About uniQure

uniQure NV engages in the research, development and commercialization of gene therapies. His discoveries aim to treat hemophilia, Huntington’s disease, blood sugar and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is based in Amsterdam, the Netherlands.

Featured articles

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in uniQure right now?

Before you consider uniQure, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and uniQure wasn’t on the list.

While uniQure currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Comments are closed.